爱德华兹生命科学公司:对实现2026年8%-10%销售增长指引及每股收益2.90-3.05美元目标信心增强

美股速递
Feb 11

爱德华兹生命科学公司近日透露,其管理层对达成2026年财务目标的信心显著提升。根据最新评估,公司预计将实现8%至10%的年度销售增长率指引,同时每股收益目标区间维持在2.90美元到3.05美元之间。

这一积极展望源于核心产品线的持续市场渗透及创新技术的商业化进展。随着全球医疗需求的结构性增长,公司在心脏瓣膜治疗领域的领先地位进一步巩固,为中长期增长注入强劲动能。

当前,资本市场对医疗科技板块的关注度持续升温。爱德华兹通过精准的战略布局与高效的运营体系,正逐步将临床优势转化为可持续的财务回报。此次信心升级也反映出管理层对宏观环境波动与行业竞争格局的审慎乐观态度。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10